Therapeutic Apheresis in Inflammatory Conditions Research
Study Citation
Achleitner M, Steenblock C, Dänhardt J, Jarzebska N, Kardashi R, Kanczkowski W, Straube R, Rodionov RN, Bornstein N, Tselmin S, Kaiser F, Bucher R, Barbir M, Wong ML, Voit-Bak K, Licinio J, Bornstein SR.
Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis.
Immediate Communication.
Study Overview
This publication examines the use of therapeutic apheresis in patients with inflammatory and immune-mediated conditions. The authors explore potential mechanisms by which extracorporeal blood filtration may alter circulating plasma components.
The paper primarily reports observational findings rather than randomised controlled trial data.
Mechanisms Discussed
The study discusses removal of:
Circulating immune complexes
Pro-inflammatory mediators
Lipid fractions
Selected plasma proteins
The authors propose that altering these components may influence inflammatory pathways.
Evidence Context
The study does not present large-scale randomised controlled data. Findings are observational and hypothesis-generating.
The authors note that further controlled research is required to clarify:
Patient selection
Treatment frequency
Duration of clinical benefit
Long-term safety outcomes
Clinical Interpretation
This publication contributes to understanding how apheresis may influence inflammatory biology. It does not establish definitive treatment guidelines or confirmed clinical efficacy.